Encompass Health approves 2025 pay raises for CEO Mark Tarr and other executives
At meetings on February 19-20, 2025, the board and its Compensation and Human Capital Committee approved annual 2025 pay increases for CEO Mark Tarr and three other named executive officers. For Tarr, base salary rises to $1.1 million, target cash bonus to $1.485 million, and target long-term equity to $6 million, and his annual personal aircraft-use allowance rises from approximately $75,000 to $100,000. The filing describes these as routine annual decisions and does not report any change in financial results, but the higher pay levels add to executive compensation costs.
Key points
- Tarr's base salary rises from $1,050,000 to $1,100,000; target cash bonus from $1,260,000 to $1,485,000; target long-term equity from $5,425,000 to $6,000,000.
- Tarr's annual personal aircraft-use allowance rises from approximately $75,000 to $100,000.
- CFO Douglas Coltharp's base salary rises from $700,000 to $750,000; target long-term equity from $1,925,000 to $2,250,000.
- Decisions were made at February 19-20, 2025 meetings, on the recommendation of the Compensation and Human Capital Committee and its independent consultant.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 21, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.